Skip to main content
SLN
NASDAQ Life Sciences

Divesiran Phase 2 Hits Primary Endpoint with 88% Response Rate in PV, Phase 3 Next

Tom Rudovsky · Reported by BusinessWire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$12.2
Mkt Cap
$564.454M
52W Low
$4.19
52W High
$12.305
52W Position info
191% above low
Off High info
at 52W high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

SLN has more than doubled off its 52-week low of $4.19.

Summary

Silence Therapeutics' divesiran crushed its Phase 2 SANRECO primary endpoint in polycythemia vera, with 88% of treated patients achieving hematocrit control without phlebotomy versus 19% on placebo (p<0.0001). Both every-6-week and every-12-week dosing showed strong efficacy (93.8% and 81.3% response rates), and phlebotomy rates plummeted to 0.2 per patient versus 2.1 for placebo. Safety was clean, consistent with earlier trials. This follows positive Phase 1 data in June and a $100M ATM shelf activation in May — the company now has $72.1M in cash and a clear path to Phase 3. The data position divesiran as a potential best-in-class siRNA for PV, a blood cancer with high cardiovascular risk. A conference call at 8:00 a.m. ET will provide more color.

Updates

  1. · SEC 8-K — The 8-K includes the press release and conference call presentation; Phase 3 trial evaluating divesiran Q12W vs. placebo is anticipated to initiate in 1H 2027.

At the time of this announcement, SLN was trading at $12.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $564.5M. The 52-week trading range was $4.19 to $12.31. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: BusinessWire.


Price Chart

Share this article

Copied!

SLN - Latest Insights

SLN
Oct 19, 2026, 8:05 AM EDT
Filing Type: 8-K
Importance Score:
10
Price at Filing: $9.10
Real-time Price: $19.80 info
Change: +$10.70 (+118%) info
Market Cap: $1.233B info
SLN
Oct 19, 2026, 8:00 AM EDT
Source: Dow Jones Newswires
Importance Score:
10
Price at Filing: $9.10
Real-time Price: $19.80 info
Change: +$10.70 (+118%) info
Market Cap: $1.233B info
SLN
Aug 14, 2026, 4:55 PM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $13.72
Real-time Price: $19.80 info
Change: +$6.08 (+44%) info
Market Cap: $1.233B info
SLN
Aug 13, 2026, 9:55 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
8
Price at Filing: $14.00
Real-time Price: $19.80 info
Change: +$5.80 (+41%) info
Market Cap: $1.233B info
SLN
Aug 13, 2026, 10:07 AM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $14.15
Real-time Price: $19.80 info
Change: +$5.65 (+40%) info
Market Cap: $1.233B info